Floatz logo

Inno-206

Fallopian Tube Carcinosarcoma

National Cancer Institute (NCI)Phase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Fallopian Tube Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
ADSORBED PURIFIED PERTUSSIS VACCINE
Mayo Clinic
Phase 2CCC
Hycamtin
Mayo Clinic
Phase 2CCC
Tetanus Toxoid
Mayo Clinic
Phase 2CCC

View all 20 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →